Najam SharifNajam Sharif, Ph.D., D.Sc., FARVO, FBPhS, FAOPT is a graduate of Southampton University, England where he received his BSc (Joint Honors: Biochemistry and Physiology), PhD (Neuroscience), and DSc (by thesis; Ophthalmology). He has been in the pharmacutical industry for >34-years holding leadership positions of increasing scope and responsibility at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Vice President, Global Alliances and External Research, Ophthalmology Innovation Center, R&D Division). He contributed to the discovery/development and US FDA approvals of multiple drugs to treat glaucoma/ocular hypertension and ocular allergies. He was recently elected as a Gold Fellow of ARVO, Fellow of British Pharmacological Society (BPS), and a Trustee of Assoc. Ocular Pharmacology & Therapeutics. He was the recipient of the inaugural Dr. Roger Vogel award for pharmaceutical research presented by the ARVO Foundation (2014), the "Sir James Black Award” for contributions to drug discovery from BPS (2017), and the awardee of the Ernst H Barany Prize for exemplary contributions to ocular pharmacology (2020). He was also elected to the Board of Directors and the Scientific Advisory Board of The Glaucoma Foundation (2020). He serves on the editorial boards of numerous scientific journals, and is an Adjunct Professor and Thesis advisor at several global universities. Read More Read Less